Proficio Capital Partners LLC Invests $719,000 in Simulations Plus, Inc. (NASDAQ:SLP)

Proficio Capital Partners LLC purchased a new position in Simulations Plus, Inc. (NASDAQ:SLP) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 25,770 shares of the technology company’s stock, valued at approximately $719,000. Proficio Capital Partners LLC owned approximately 0.13% of Simulations Plus at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Barclays PLC increased its position in shares of Simulations Plus by 390.6% during the 3rd quarter. Barclays PLC now owns 28,473 shares of the technology company’s stock valued at $911,000 after purchasing an additional 22,669 shares during the last quarter. Geode Capital Management LLC raised its position in Simulations Plus by 4.4% during the third quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock valued at $14,367,000 after purchasing an additional 18,924 shares during the period. State Street Corp increased its position in Simulations Plus by 4.7% during the third quarter. State Street Corp now owns 640,303 shares of the technology company’s stock valued at $20,503,000 after acquiring an additional 28,953 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Simulations Plus by 106.0% in the third quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company’s stock worth $1,517,000 after purchasing an additional 24,371 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of Simulations Plus by 402.9% during the third quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company’s stock worth $1,279,000 after purchasing an additional 32,002 shares during the last quarter. 78.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on SLP. KeyCorp upped their target price on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. Finally, Stephens began coverage on shares of Simulations Plus in a report on Friday, November 15th. They set an “overweight” rating and a $39.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $49.40.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the transaction, the director now owns 3,402,584 shares of the company’s stock, valued at $115,381,623.44. This represents a 0.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 19.40% of the company’s stock.

Simulations Plus Stock Performance

Shares of SLP opened at $28.23 on Friday. The stock has a 50 day moving average price of $31.78 and a 200 day moving average price of $31.61. Simulations Plus, Inc. has a one year low of $24.00 and a one year high of $51.22. The stock has a market capitalization of $567.20 million, a price-to-earnings ratio of 70.58 and a beta of 0.89.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.